User login
Key clinical point: In patients with sentinel node (SN)-positive cT1-2 primary breast cancer (BC), both axillary radiotherapy (ART) and axillary lymph node dissection (ALND) led to similar recurrence rates, but the rate of lymphedema was lower with ART.
Major finding: The 10-year axillary recurrence rates were similar between the ALND and ART treatment groups (hazard ratio 1.71; 95% CI 0.67-4.39), with a lower proportion of patients reporting lymphedema in the ART vs ALND group (28.6% vs 44.2%).
Study details: Findings are from the phase 3, AMAROS trial including 1425 patients with clinically node-negative cT1-2 primary BC and a positive SN who were randomly assigned to receive ALND or ART.
Disclosures: This trial was sponsored by the European Organization for Research and Treatment of Cancer. The authors declared serving in leadership, consulting, or advisory roles or receiving honoraria or travel, accommodation, and expenses from several sources.
Source: Bartels SAL, Donker M et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2022 (Nov 16). Doi: 10.1200/JCO.22.01565
Key clinical point: In patients with sentinel node (SN)-positive cT1-2 primary breast cancer (BC), both axillary radiotherapy (ART) and axillary lymph node dissection (ALND) led to similar recurrence rates, but the rate of lymphedema was lower with ART.
Major finding: The 10-year axillary recurrence rates were similar between the ALND and ART treatment groups (hazard ratio 1.71; 95% CI 0.67-4.39), with a lower proportion of patients reporting lymphedema in the ART vs ALND group (28.6% vs 44.2%).
Study details: Findings are from the phase 3, AMAROS trial including 1425 patients with clinically node-negative cT1-2 primary BC and a positive SN who were randomly assigned to receive ALND or ART.
Disclosures: This trial was sponsored by the European Organization for Research and Treatment of Cancer. The authors declared serving in leadership, consulting, or advisory roles or receiving honoraria or travel, accommodation, and expenses from several sources.
Source: Bartels SAL, Donker M et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2022 (Nov 16). Doi: 10.1200/JCO.22.01565
Key clinical point: In patients with sentinel node (SN)-positive cT1-2 primary breast cancer (BC), both axillary radiotherapy (ART) and axillary lymph node dissection (ALND) led to similar recurrence rates, but the rate of lymphedema was lower with ART.
Major finding: The 10-year axillary recurrence rates were similar between the ALND and ART treatment groups (hazard ratio 1.71; 95% CI 0.67-4.39), with a lower proportion of patients reporting lymphedema in the ART vs ALND group (28.6% vs 44.2%).
Study details: Findings are from the phase 3, AMAROS trial including 1425 patients with clinically node-negative cT1-2 primary BC and a positive SN who were randomly assigned to receive ALND or ART.
Disclosures: This trial was sponsored by the European Organization for Research and Treatment of Cancer. The authors declared serving in leadership, consulting, or advisory roles or receiving honoraria or travel, accommodation, and expenses from several sources.
Source: Bartels SAL, Donker M et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2022 (Nov 16). Doi: 10.1200/JCO.22.01565